173 related articles for article (PubMed ID: 12063677)
1. P53 gene mutations: case study of a clinical marker for solid tumors.
Liu MC; Gelmann EP
Semin Oncol; 2002 Jun; 29(3):246-57. PubMed ID: 12063677
[TBL] [Abstract][Full Text] [Related]
2. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
3. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
4. Implications of the p53 tumor-suppressor gene in clinical oncology.
Chang F; Syrjänen S; Syrjänen K
J Clin Oncol; 1995 Apr; 13(4):1009-22. PubMed ID: 7707100
[TBL] [Abstract][Full Text] [Related]
5. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
Crowe DL; Sinha UK
Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195
[TBL] [Abstract][Full Text] [Related]
6. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.
Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA
Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors.
Kandioler D; Dekan G; End A; Pasching E; Buchmayer H; Gnant M; Langmann F; Mannhalter C; Eckersberger F; Wolner E
J Thorac Cardiovasc Surg; 1996 Apr; 111(4):827-31; discussion 832. PubMed ID: 8614143
[TBL] [Abstract][Full Text] [Related]
8. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
Mendoza-Rodríguez CA; Cerbón MA
Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
[TBL] [Abstract][Full Text] [Related]
9. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
10. [Can analysis of the molecular status of the p53 gene contribute to improving the therapeutic strategy for breast carcinoma?].
Ricevuto E; Marchetti P; Cannita K; De Galitiis F; Di Rocco ZC; Tessitore A; Martella F; Bisegna R; Porzio G; Bafile A; Vicentini R; Resta V; Mattucci S; Ventura T; Martinotti S; de Rubeis GP; Ficorella C
Tumori; 2003; 89(4 Suppl):197-9. PubMed ID: 12903592
[TBL] [Abstract][Full Text] [Related]
11. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.
Koch WM; Brennan JA; Zahurak M; Goodman SN; Westra WH; Schwab D; Yoo GH; Lee DJ; Forastiere AA; Sidransky D
J Natl Cancer Inst; 1996 Nov; 88(21):1580-6. PubMed ID: 8901856
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology of colorectal cancer.
Gryfe R; Swallow C; Bapat B; Redston M; Gallinger S; Couture J
Curr Probl Cancer; 1997; 21(5):233-300. PubMed ID: 9438104
[TBL] [Abstract][Full Text] [Related]
13. Pattern of p53 gene mutations in breast cancers of women of the midwestern United States.
Sommer SS; Cunningham J; McGovern RM; Saitoh S; Schroeder JJ; Wold LE; Kovach JS
J Natl Cancer Inst; 1992 Feb; 84(4):246-52. PubMed ID: 1734086
[TBL] [Abstract][Full Text] [Related]
14. p53 immunostaining is correlated with reduced survival and is not correlated with gene mutations in resected pulmonary large cell carcinomas.
Massoni Neto LM; Bianchi CP; Ab'Saber AM; Parra ER; Takagaki T; Pereira JC; Soares FA; Leite K; Capelozzi VL
Braz J Med Biol Res; 2007 Aug; 40(8):1045-53. PubMed ID: 17665040
[TBL] [Abstract][Full Text] [Related]
15. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids.
Fliss MS; Usadel H; Caballero OL; Wu L; Buta MR; Eleff SM; Jen J; Sidransky D
Science; 2000 Mar; 287(5460):2017-9. PubMed ID: 10720328
[TBL] [Abstract][Full Text] [Related]
16. p53 tumor suppressor gene as a clonal marker in head and neck squamous cell carcinoma: p53 mutations in primary tumor and matched lymph node metastases.
Tjebbes GW; Leppers vd Straat FG; Tilanus MG; Hordijk GJ; Slootweg PJ
Oral Oncol; 1999 Jul; 35(4):384-9. PubMed ID: 10645403
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer.
Brachman DG; Graves D; Vokes E; Beckett M; Haraf D; Montag A; Dunphy E; Mick R; Yandell D; Weichselbaum RR
Cancer Res; 1992 Sep; 52(17):4832-6. PubMed ID: 1324797
[TBL] [Abstract][Full Text] [Related]
18. Carcinogen-specific mutations in the p53 tumor suppressor gene in lung cancer.
Kandioler D; Foedinger M; Mueller MR; Eckersberger F; Mannhalter C; Wolner E
J Thorac Cardiovasc Surg; 1994 Apr; 107(4):1095-8. PubMed ID: 8159032
[TBL] [Abstract][Full Text] [Related]
19. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
[TBL] [Abstract][Full Text] [Related]
20. Biological and clinical importance of the p53 tumor suppressor gene.
Velculescu VE; El-Deiry WS
Clin Chem; 1996 Jun; 42(6 Pt 1):858-68. PubMed ID: 8665676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
